ZCA
TEVA icon

Zeke Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Zeke Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,030
Closed -$410K – 643
2018
Q3 		$410K Buy
19,030
+400
+2% +$9.29K 0.03% 447
2018
Q2 		$453K Sell
18,630
-1,584
-8% -$32.3K 0.04% 318
2018
Q1 		$345K Buy
20,214
+6,576
+48% +$128K 0.03% 415
2017
Q4 		$258K Buy
+13,638
New +$205K 0.03% 426
2017
Q3 		– Sell
-7,576
Closed -$252K – 444
2017
Q2 		$252K Buy
7,576
+919
+14% +$28.4K 0.05% 228
2017
Q1 		$214K Buy
+6,657
New +$227K 0.04% 238

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Zeke Capital Advisors's TEVA Position: Q4 2018 in Review

Zeke Capital Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 19,030 shares — an estimated $410K sold.

Zeke Capital Advisors first reported a position in TEVA in Q1 2017 and held it in 6 quarters. The position peaked at $453K in Q2 2018. 551 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Zeke Capital Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Zeke Capital Advisors sold 19,030 Teva Pharmaceuticals shares in Q4 2018, an estimated $410K.
  • Zeke Capital Advisors first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 6 quarters.
  • Zeke Capital Advisors's Teva Pharmaceuticals position peaked at $453K in Q2 2018.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Zeke Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.